[CAS NO. 55079-83-9] Acitretin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [55079-83-9]

Catalog

HY-B0107

Brand

MCE

CAS

55079-83-9

DESCRIPTION [55079-83-9]

Overview

MDL	MFCD00866632
Molecular Weight	326.43
Molecular Formula	C21H26O3
SMILES	CC(/C=C/C(C(C)=CC(OC)=C1C)=C1C)=C\C=C\C(C)=C\C(O)=O

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

Acitretin (Ro 10-1670) is a second-generation, systemic retinoid that has been used in the treatment of psoriasis. Acitretin also can be used for the research of Alzheimer’s disease ^[1] ^[2] ^[3] .

In Vivo

Acitretin (10 mg/kg; i.p. for 7 days) increases IL-6 in the central nervous system of Alzheimer’s disease model mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01094717	University of Utah	Psoriasis	January 2010	Not Applicable
NCT02181790	Icahn School of Medicine at Mount Sinai	Psoriasis, Skin or Nails	June 2014	Phase 4
NCT00936065	Pfizer	Moderate to Severe Psoriasis	July 2009	Phase 4
NCT00156247	University of Medicine and Dentistry of New Jersey\|Connetics Corp.\|Rutgers, The State University of New Jersey	Psoriasis	September 2005	Phase 2
NCT02191020	Xijing Hospital\|Henan Provincial People´s Hospital\|The First Affiliated Hospital of Dalian Medical University	Psoriasis	February 2013	Not Applicable
NCT01299220	University of Pittsburgh\|OSI Pharmaceuticals	Skin Rash	November 2010	Phase 4
NCT01443338	Ministry of Health, China	Psoriasis Vulgaris	September 2011	Phase 4
NCT01228409	Frankel, Amylynne, M.D.\|Stiefel, a GSK Company	Psoriasis	October 2010	Phase 4
NCT00395941	Postgraduate Institute of Medical Education and Research	Psoriasis	December 2006	Phase 2
NCT01078168	K. Lieb\|Alzheimer Forschungsinitiative e.V. (AFI)\|Johannes Gutenberg University Mainz	Alzheimer Disease	March 2010	Phase 2
NCT05401006	South Valley University	Psoriasis	June 5, 2021	Phase 4
NCT02050321	University of Arizona	Malignant Melanoma	December 2013	Phase 2
NCT00723437	Istituti Fisioterapici Ospitalieri\|University of Bologna	Psoriasis	January 2005	Phase 4
NCT00488384	Günther Hofbauer\|University of Zurich	Carcinoma, Squamous Cell	June 2007	Phase 4
NCT02715960	Central South University	Psoriasis Vulgaris	December 2015	Phase 2
NCT00644384	Mayo Clinic\|National Cancer Institute (NCI)	Non-melanomatous Skin Cancer	February 2003	Not Applicable
NCT05203354	Mahmoud Ahmed Ali Ahmed\|Aswan University Hospital	Psoriasis	September 1, 2018	Phase 4
NCT00003611	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Non-melanomatous Skin Cancer	May 2000	Not Applicable
NCT00002143	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	HIV Infections\|Psoriasis		Phase 3
NCT00707070	Universita di Verona	Chronic Plaque Psoriasis	September 2008	Phase 4
NCT05184348	South Valley University	Psoriasis Vulgaris	November 23, 2021	Phase 4
NCT02330380	University Hospitals Cleveland Medical Center\|National Psoriasis Foundation	Psoriasis\|Inflammation	April 2013
NCT01812954	Jochen Schmitt.\|Merck Sharp & Dohme LLC\|Technische Universität Dresden	Psoriasis	March 2013
NCT03753867	Ottawa Hospital Research Institute	HIV Infections	January 7, 2019	Phase 1
NCT04239859	Singapore General Hospital\|Translational Immunology Institute	Plaque Psoriasis	January 2022	Phase 4
NCT01039142	Postgraduate Institute of Medical Education and Research	Psoriasis	March 2008	Phase 4
NCT01545284	Innovaderm Research Inc.\|Tribute Pharmaceuticals	Chronic Hand Dermatitis	March 2012	Phase 2\|Phase 3
NCT04245319	Cairo University	Hyperlipidemias\|Xerosis\|Depression\|Liver Diseases	January 1, 2020	Not Applicable
NCT04537689	Singapore General Hospital\|Translational Immunology Institute	Plaque Psoriasis	December 10, 2020	Phase 4
NCT00832364	Stiefel, a GSK Company\|GlaxoSmithKline	Plaque Psoriasis	October 2009	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 20 mg/mL ( 61.27 mM ; Need ultrasonic)

H ₂ O : < 0.1 mg/mL (ultrasonic) (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0634 mL	15.3172 mL	30.6344 mL
5 mM	0.6127 mL	3.0634 mL	6.1269 mL
10 mM	0.3063 mL	1.5317 mL	3.0634 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 2 mg/mL (6.13 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2 mg/mL (6.13 mM); Suspended solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2 mg/mL (6.13 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2E,4E,6E,8E)-

2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)-

(2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid

Ro 10-1670

Etretin

Acitretin

Neotigason

all-trans-Acitretin

TMMP

Soriatane

Ro 10-1670/000

Acitretinoin